NCT03291977View on ClinicalTrials.gov

Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)

PHASE3CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

October 5, 2017

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2022

Conditions
Glioblastoma, Adult
Interventions
DRUG

Fluorescéine Sodique Faure

Fluorescéine Sodique Faure given intravenously during the induction of the anesthesia, at the dose of 3mg/kg, diluted in 50mL of physiological serum, in 10 minutes.

PROCEDURE

White-light surgery

The surgery will be performed under classical conditions

Trial Locations (1)

Unknown

CHU Rennes, Rennes

All Listed Sponsors
lead

Rennes University Hospital

OTHER

NCT03291977 - Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME) | Biotech Hunter | Biotech Hunter